Global Cancer Drug Spend to Nearly Double in the Next Five Years | IQVIA Global Drug Spend Report
January 23rd 2023Biosimilars will have limited effect on the oncology drug expenditures, according to IQVIA. Spending on obesity drugs may increase tenfold, depending on guidelines and payer coverage.
Read More
Spending using net prices (prices after discounts and rebates are factored in) will grow between -1% and 2% between 2023 through 2027, say IQVIA analysts in the company's Global Use of Medicines report. Patent expiration and competition from generics and biosimilars and the healthcare-related provisions of the Inflation Reduction Act will push down spending, predict IQ.
Read More
A Dip in MSSP ACO Numbers, But Up Is the Direction in ACO Reach, CMS Announces
January 17th 2023CMS announced today that 456 accountable care organizations (ACOs) will participate in Medicare Shared Savings Plan program in 2023, a decrease from the 483 ACOs that participated last year. But 132 ACOs have signed up to participate in the ACO REACH, an increase from 99 last year.
Read More
Fluvoxamine Effective Against COVID-19? Apparently Not Now.
January 12th 2023Results reported today on the JAMA website show no benefit from repurposing the SSRI as a COVID-19 treatment drug. Earlier results suggesting that fluvoxamine might be an effective treatment were from trials conducted earlier in the pandemic when vaccines weren’t available and other variants were circulating.
Read More
What's on the Mind of Perry Cohen of The Pharmacy Group?
January 11th 2023In this debut podcast series of What's on Your Mind podcast, Perry Cohen, Pharm.D., CEO of The Pharmacy Group, recently shared his thoughts on the current state of healthcare and especially the management of pharmacy costs. This new monthly series brings listeners into the minds of Managed Healthcare Executive's® Editorial Advisory Board members. Cohen has decades of experience in managed care and has been on the editorial advisory board since 1994.
Read More
FDA Approves New Alzheimer's Drug, Leqembi. Can It Escape Aduhelm's Fate?
January 7th 2023Leqembi's starting price is almost half of what Aduhelm's was and the FDA-approved label narrows use to people with early disease. But Medicare coverage restrictions may still apply and there is concern about a side effect called ARIA (amyloid related imaging abnormalities).
Read More
Disparities in HIV Prescribing Narrowed As Federal Guidelines Changed, Study Finds
January 4th 2023But disparities among White, Black and Hispanic patients were largest among those with private insurance, according to findings reported in JAMA. The researchers speculate that differences in dealing with prior authorization may have widened disparities in the prescribing integrase strand transfer inhibitors (INSTIs).
Read More
Wanted: Biomarkers for MS. Could MicroRNAs Be the Answer?
December 13th 2022A recently published review paper looked at microRNAs, which play a key role in gene expression. Much more research is needed, the researchers concluded, to fill in the gaps of how microRNAs might be used to monitor how people with multiple sclerosis (MS) response to the growing number of MS treatments.
Read More
Evidence that people with multiple sclerosis (MS) benefit from exercise is accumulating researchers should be careful about using standard definitions of exercise and start collecting and reporting data on adverse event, says the National MS physical wellness research working group.
Read More
COVID-19 Associated With Decreased Sperm Concentration, Study Finds
December 2nd 2022Evidence that COVID-19 might affect male fertility is accumulating, although it is an incomplete picture and there is no final word on the subject. This study found a possible effect on concentration but not on sperm motility or morphology.
Read More
COVID-19 Pandemic Caused Only a Dip in HIV Prevention, Care Services
December 1st 2022Results reported by CDC researchers show a sharp drop-off in HIV prevention and care services, such as preexposure prophylaxis prescriptions, in the second quarter of 2020 but then a rebound in third quarter.
Read More
Demand Up, Supply Down = Adderall Shortage
December 1st 2022Short-term manufacturing problems are happening as the demand for Adderall and other stimulant medications for ADHD have increased. Data from Arrive Health show a marked increase in ADHD medication prescriptions for people in their 30s.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Price and End Points. For Cancer Drugs, There Is a Disconnect, Research Finds
October 31st 2022Overall survival is considered a more definitive end point. But according to Vinay Prasad, M.D., M.P.H., and colleagues , drugs approved based on progression-free survival and overall response rate were priced higher than those approved based on overall survival.
Read More
The FDA approved Tecvayli (teclistamab) yesterday after approving two CAR-T therapies as late-line treatments for multiple myeloma earlier this year. Because it is ‘off the shelf,’ Tecvayli may have advantages over the CAR-T therapies, which are custom made for each patient and involve harvesting the patient's T cells.
Read More
The 'Niche Solutions' of Value-based Care, per Doug Chaet of Value Evolutions
October 19th 2022Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing and CMS value-based trends vs commercial payer trends. Chaet also addressed the status of select payment models like bundled and episodic, and more.
Read More